# Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT02312245** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **DRUG:** Topotecan Hydrochloride

## Key facts

- **NCT ID:** NCT02312245
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2023-04-24
- **Final completion:** 2023-04-24
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312245, "Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02312245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*